DOI: 10.21276/sajp.2018.7.3.2

Pages: 115-119

Various groups of oral hypoglycemic agents (OHAs) are recently available, but there is a need for agents with different mechanisms of action that achieve better efficacy and can be used either as monotherapy or in combination with treatment regimens. Dipeptidyl peptidase-4 inhibitors improve glycemic control in patients with type 2 diabetes mellitus (T2DM) when used as monotherapy or in combination with other OHAs. The main aim of the present study is to compare the effects of Saxagliptin versus Glimepiride on efficacy of treatment in patients with T2DM in combination with metformin. A retrospective observational study will be performed on patients each in (Saxagliptin+Metformin) and (Glimepiride+Metformin) group, who are receiving treatment for at least 12 weeks. Glycated hemoglobin (HBA1c) will be the chief parameter of efficacy. At 12 weeks both groups (Saxagliptin and Glimepiride) produced significant